UCLA Medical Center Internal Medicine

Topics

• Atrial Fibrillation Management and Outcomes 53
• Retinal Diseases and Treatments 45
• Systemic Sclerosis and Related Diseases 33
• Retinal and Macular Surgery 27
• Glaucoma and retinal disorders 23
• Trypanosoma species research and implications 22
• HIV Research and Treatment 18
• Inflammatory Bowel Disease 18
• Parkinson's Disease Mechanisms and Treatments 18
• Diversity and Career in Medicine 17
• Emergency and Acute Care Studies 17
• Ophthalmology and Visual Impairment Studies 17

Most cited

1. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.

   Lancet (London, England) · 2022 · 670 citations · Hugh Lin

2. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.

   Nature medicine · 2023 · 572 citations · Afshin Gabayan

3. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.

   Ophthalmology · 2024 · 192 citations · Hugh Lin

4. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.

   Lancet (London, England) · 2022 · 396 citations · Hugh Lin

5. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.

   Ophthalmology · 2024 · 135 citations · Hugh Lin

6. Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.

   The New England journal of medicine · 2025 · 95 citations ·